Skip to content

Effects of continuous ingestion of partially hydrolyzed guar gum on soft stool by intestinal bacterial flora

Effects of continuous ingestion of partially hydrolyzed guar gum on soft stool by intestinal bacterial flora - Effects of partially hydrolyzed guar gum on soft stool

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030184
Enrollment
40
Registered
2018-12-01
Start date
2017-12-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Oral intake of the food containing partially hydrolyzed guar gum (continuous) Oral intake of placebo food (continuo us)

Sponsors

imeQ Co.Ltd.
Lead Sponsor
Kyoto Prefectural University of Medicine
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese male and female volunteers (20 to 49 years). 2. Healthy people. 3. Who has trends of diahhrea. 4. Who can give informed consent by the document based on the individual's intention before the start of the study. 5. Who can visit the clinic during the test period.

Exclusion criteria

Exclusion criteria: People who meet any of the following conditions will be excluded. 1. Who is likely to be inflammatory bowel disease, gastrointestinal ulcers, pancreatitis, celiac disease, lactose intolerance, protozoan infection, parasitic infection, other organic gastrointestinal disease or pregnant women. 2. Who uses commercially available drug or a quasi-drugs, for the prevention and treatment of diarrhea with abdominal pain and abdominal discomfort, on a daily basis. 3. Who is currently going to hospital for the treatment of diarrhea with abdominal pain and abdominal discomfort. 4. Who is judged by principal investigator to require medical treatment because of severe diarrhea with abdominal pain and abdominal discomfort. 5. Who has been diagnosed with irritable bowel syndrome. 6. Who has experienced a gastrointestinal surgery, excluding operation for appendicitis. 7. Who is in breast-feeding or pregnancy, or wishes to become pregnant during the study period. 8. Who has been treated for some systemic disease. 9. Who uses non-steroidal anti-inflammatory drugs, steroids or antibiotics on a daily basis. 10. Who is smoker -excluding who have quitted smoking for one year or more. 11. Who has an abnormality in the blood test excluding who is judged by principal investigator as in range of physiological variation. 12. Who had participated in a clinical trial within 60 days before a screening test. 13. Who is irresponsible-mental illness, dementia etc. 14. Who is sufferring or have sufferred allergic reaction to food or drug. 15. Who is judged as ineligible by principal investigators or researchers.

Design outcomes

Primary

MeasureTime frame
Bowel Survey

Secondary

MeasureTime frame
Intestinal bacterial Flora, blood metabolite, questionnaire

Countries

Japan

Contacts

Public ContactZenta Yasukawa

Taiyo Kagaku Co., Ltd. Nutrition division

zyasukawa@taiyokagaku.co.jp059-347-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026